Cancers (Jun 2022)

Liquid Biopsy Landscape in Patients with Primary Upper Tract Urothelial Carcinoma

  • Stephanie N. Shishido,
  • Alireza Ghoreifi,
  • Salmaan Sayeed,
  • George Courcoubetis,
  • Amy Huang,
  • Brandon Ye,
  • Sankalp Mrutyunjaya,
  • Inderbir S. Gill,
  • Peter Kuhn,
  • Jeremy Mason,
  • Hooman Djaladat

DOI
https://doi.org/10.3390/cancers14123007
Journal volume & issue
Vol. 14, no. 12
p. 3007

Abstract

Read online

Urothelial carcinomas (UCs) are a broad and heterogeneous group of malignancies, with the prevalence of upper tract urothelial carcinoma (UTUC) being rare, accounting for only 5–10% of total malignancies. There is a need for additional toolsets to assist the current clinical paradigm of care for patients with UTUC. As a non-invasive tool for the discovery of cancer-related biomarkers, the liquid biopsy has the potential to represent the complex process of tumorigenesis and metastasis. Herein, we show the efficacy of the liquid biopsy as a source of biomarkers for detecting UTUC. Using the third-generation high-definition single-cell assay (HDSCA3.0) workflow, we investigate liquid biopsy samples collected from patients with UTUC and normal donors (NDs) to provide critical information regarding the molecular and morphological characteristics of circulating rare events. We document several important findings from the liquid biopsy analysis of patients diagnosed with UTUC prior to surgery: (1) Large extracellular vesicles (LEVs) and circulating tumor cells (CTCs) are detectable in the peripheral blood. (2) The rare-event profile is highly heterogeneous. (3) Clinical data elements correlate with liquid biopsy analytes. Overall, this study provides evidence for the efficacy of the liquid biopsy in understanding the biology of UTUC with the future intent of informing clinical decision making, ultimately improving patient outcomes.

Keywords